Ken Griffin Lumos Pharma, Inc. Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.19 - $3.04 $11,955 - $16,595	5,459 Added 41.09%	18,745 $43,000
Q1 2024 May 15, 2024	BUY	$2.64 - $3.22 $35,075 - $42,780	13,286 New	13,286 $37,000
Q1 2023 May 15, 2023	SELL	$3.16 - $4.0 $7,403 - $9,372	-2,343 Reduced 13.1%	15,548 $51,000
Q4 2022 Feb 14, 2023	BUY	$3.05 - $9.52 $54,567 - $170,322	17,891 New	17,891 $64,000

2.2M

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.